Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.71. Which is the better fit depends on your goals.
| ALNY | USIG | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Fixed Income |
52-Week High | $491.22 | $52.69 |
52-Week Low | $278.09 | $50.56 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
USIG trades at $50.705, down 0.15% on the day, with technical indicators showing a bearish trend from moving averages while oscillators are neutral. Recent corporate actions include dividend payments, with the latest being $0.20 paid on 07 Jul 2026. Short interest surged 63.4% in April 2026, indicating increased bearish sentiment among traders, per Defense World on 2026-04-27.
The outlook remains cautious due to weak technical signals and rising short interest, though dividends provide income support. Key risks include market volatility and institutional selling, as seen with Fifth Third Securities reducing its stake by 54.7% in Q1 2026. Investors should weigh income stability against bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
